#Gilead Sciences

Researchers are looking for ways to reduce the doses needed for on-demand PrEP and the 30-day duration recommended for PEP.

What has happened since health experts identified an HIV cluster in Huntington, West Virginia, in 2018?

Gilead Sciences is giving its antiviral remdesivir to nearly 1,000 people as part of two clinical trials.

Gilead’s HIV capsid inhibitor might need dosing only every six months

Plus: Top 10 philanthropic funders of HIV, according to the latest report from Funders Concerned About AIDS

Advocates claim Gilead and others unfairly limited competition for HIV combination pills.

Canadian researchers analyzed the reasons why people declined a nurse’s offer of PrEP.

Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.

Here are the HIV treatment news stories with the most views this year.

Plus: Tell your representatives to support the PrEP Access and Coverage Act. Here’s how.

The funding arrives via Gilead Sciences’ COMPASS Initiative.

The U.S. Health Department launched Ready, Set, PrEP to provide the HIV prevention med at no cost.

An analysis of veterans seeking PrEP found that they often had to be extraordinarily persistent in their efforts to receive a prescription.

Funding arrives via Gilead Sciences and its TRANScend Community Impact Fund.

Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.

The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.